Journal of Medicinal Chemistry · 2018 · 53 citations · 20 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyMolecular PharmacologyCombination ChemotherapyLung Cancer PharmacotherapyOncology PharmacologyAnticancer ActivityAnticancer ChemotherapyCancer Cell Line ModelsNon-small Cell Lung Cancer TherapyProgrammed Death-ligand 1 InhibitionProgrammed Death-ligand 1 InhibitorsProgrammed Death-ligand 1 SignalingTherapeutic Growth Inhibition
We designed and synthesized quinazolin-2,4-dione-based hydroxamic acids to serve as selective competitive inhibitors of histone deacetylase-6 (HDAC6). The most potent and selective compound, 3d (IC50, 4 nM, HDAC6; IC50 > 10 μM, HDAC1), substantially increased acetylation of α-tubulin instead of histones in the lung cancer cell line, LL2. Paclitaxel in combination with 3d had a synergistic anticancer effect on reduction of programmed death-ligand 1 expression in LL/2 cells. When given orally, 3d was mainly found to locate in the liver and lungs, at a concentration 18- to 70-fold greater, respectively, than in plasma. As an orally active HDAC6 inhibitor, 3d (20 mg/kg) potentiated paclitaxel antitumor activity (percentage tumor growth inhibition, 67.5%) in a xenograft syngeneic non-small cell lung cancer mouse model.
20
HDAC6 Modulates Cell Motility by Altering the Acetylation Level of Cortactin
Xiaohong Zhang, Zhigang Yuan, Yingtao Zhang et al. · Molecular Cell · 2007 · 725 citations · Full text
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
John R. Somoza, R.J. Skene, B.A. Katz et al. · Structure · 2004 · 698 citations · Full text
Loredana Santo, Teru Hideshima, Andrew L. Kung et al. · Blood · 2012 · 601 citations · Full text